Lumosa Therapeutics Co., Ltd. (TPEX: 6535)

Market Cap	61.44B
Revenue (ttm)	37.82M
Net Income (ttm)	-388.80M
Shares Out	164.93M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,191,138
Open	332.00
Previous Close	325.50
Day's Range	323.00 - 358.00
52-Week Range	61.40 - 400.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. L...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2023, Lumosa Therapeutics's revenue was 56.92 million, an increase of 113.63% compared to the previous year's 26.64 million. Losses were -238.04 million, -51.88% less than in 2022.